Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Ronald Paquette, M.D
Ronald Paquette, M.D


Cancer/Medical Oncology

General Information:



Clinical Professor, Department of Medicine, Hematology/Oncology
Member, JCCC Cancer and Stem Cell Biology Program Area


Hematology/Oncology, UCLA School of Medicine, 1987 - 1990
Internal Medicine, UCLA School of Medicine, 1985 - 1987
Internal Medicine, UCLA School of Medicine, 1984 - 1985
Medical Degree:
M.D., Ohio State University College of Medicine, 1984


Board Certification(s):
Medical Oncology, American Board of Internal Medicine, 1989
Internal Medicine, American Board of Internal Medicine, 1988

Contact Information:

(310) 206-6931 or (310) 206-6909 UCLA Oncology Center information and patient appointments

Practice Information:

Clinical Interest(s):
Aplastic Anemia
Bone Marrow Transplantation
Chronic Myelogenous Leukemia
General Hematology
Hematologic Malignancies
Multiple Myeloma
Myelodysplastic Syndrome
Myeloproliferative Disorders

Scientific Interest(s):

Dr. Ronald Paquette conducts clinical research for the treatment of myelodysplastic syndrome (MDS) and related disorders. He is a longstanding member of the Medical Advisory Board for the Aplastic Anemia & MDS International Foundation, Inc., an organization dedicated to providing support for patients with bone marrow failure. Paquette also has a special interest in new treatments for chronic myeloid leukemia and other myeloproliferative disorders. He is an attending physician on the UCLA Bone Marrow Transplant Service and is the Medical Director of the Bone Marrow and Stem Cell Processing Laboratory.

Selected Cancer-Related Publications:

Deininger MW, Cortes J, Paquette R, Park B, Hochhaus A, Baccarani M, Stone R, Fischer T, Kantarjian H, Niederwieser D, Gambacorti-Passerini C, So C, Gathmann I, Goldman JM, Smith D, Druker BJ, Guilhot F. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer. 2007 Oct 1;110(7):1509-19.

Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest. 2007; 117:2562-2569.

Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006; 354(24): 2531-41.

DeAngelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette RL, Klisovic RB, Caligiuri MA, Cooper MR, Lecerf JM, Karol MD, Sheng S, Holford N, Curtin PT, Druker BJ, Heinrich MC. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood. 2006; 108(12): 3674-81.

O'Farrell AM, Foran JM, Fiedler W, Serve H, Paquette RL, Cooper MA, Yuen HA, Louie SG, Kim H, Nicholas S, Heinrich MC, Berdel WE, Bello C, Jacobs M, Scigalla P, Manning WC, Kelsey S, Cherrington JM. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res. 2003; 9(15): 5465-76.